Enzalutamide companion diagnostic - Astellas Pharma/ Medivation/ NanoString Technologies

Drug Profile

Enzalutamide companion diagnostic - Astellas Pharma/ Medivation/ NanoString Technologies

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma; Medivation; NanoString Technologies
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 28 Sep 2016 Medivation has been acquired by Pfizer
  • 07 Jan 2016 Preclinical trials in Breast cancer (Diagnosis) in USA (unspecified route)
  • 07 Jan 2016 Nanostring, Medivation and Astellas agree to co-develop enzalutamide companion diagsnotic in USA for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top